Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Inogen, Inc. is a medical technology company focused on the development, manufacture, and commercialization of portable oxygen concentrators used in long-term oxygen therapy. The company operates within the medical devices and respiratory care industries, primarily serving patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s core value proposition centers on enabling mobility and improving quality of life through lightweight, portable oxygen delivery systems.
The company generates revenue primarily through the sale and rental of its proprietary portable oxygen concentrators and related accessories, distributed via direct-to-consumer channels, business-to-business relationships, and international distributors. Inogen is differentiated by its emphasis on portability, battery-powered oxygen delivery, and a vertically integrated model encompassing product design, manufacturing, and sales. Founded in 2001, the company evolved from a technology innovator in oxygen delivery to a publicly traded enterprise following its initial public offering in 2014, expanding its reach across homecare providers and global markets.
Business Operations
Inogen organizes its operations around three primary business segments: Domestic Business-to-Business, Domestic Direct-to-Consumer, and International. The Domestic Business-to-Business segment sells oxygen concentrators to home medical equipment providers, while the Domestic Direct-to-Consumer segment focuses on direct sales and rentals to patients in the United States. The International segment distributes products through third-party distributors and, in some cases, direct sales in select markets outside the U.S.
The company designs and manufactures its portable oxygen concentrators internally, controlling key technologies related to oxygen separation, battery systems, and device miniaturization. Inogen operates manufacturing and refurbishment facilities and maintains a service infrastructure to support patients throughout the product lifecycle. Its revenue model includes device sales, recurring rental income, and accessory sales, with international revenue representing a smaller but strategically important portion of total revenue.
Strategic Position & Investments
Inogen’s strategic direction emphasizes expanding adoption of portable oxygen therapy, increasing penetration in international markets, and improving operational efficiency. Growth initiatives have included product line enhancements, marketing investments in direct-to-consumer channels, and efforts to strengthen relationships with homecare providers. The company has historically focused on organic growth rather than large-scale acquisitions, with capital allocation directed toward research and development and manufacturing capabilities.
The company’s portfolio consists primarily of wholly owned operations rather than a broad network of subsidiaries or joint ventures. Inogen continues to invest in next-generation portable oxygen concentrator technologies aimed at reducing device weight, extending battery life, and improving reliability. Its strategic positioning reflects a focus on patient mobility and independence within the broader shift toward home-based and ambulatory care.
Geographic Footprint
Inogen is headquartered in Goleta, California, and its primary operations are concentrated in the United States, which represents the majority of revenue. The company maintains manufacturing, logistics, and service operations domestically to support both direct-to-consumer and business-to-business customers.
Internationally, Inogen has a presence across Europe, Asia, and other select global markets through distributor relationships and limited direct operations. While international revenue is smaller relative to the U.S. business, these markets are viewed as long-term growth opportunities as awareness of portable oxygen therapy increases and healthcare systems continue to shift toward outpatient and home-based care models.
Leadership & Governance
Inogen was co-founded by Alison Bauerlein, who played a key role in the company’s early technology development and commercialization strategy. The leadership team is responsible for executing a strategy centered on operational discipline, product innovation, and sustainable growth within the respiratory care market. Public disclosures emphasize a focus on patient-centric design, regulatory compliance, and long-term shareholder value.
Key executives include:
- Elizabeth Perez – President and Chief Executive Officer
- Bert Verhulst – Chief Financial Officer
- Kevin Smith – Chief Operating Officer (Data inconclusive based on available public sources regarding current role status)
The board and executive leadership oversee corporate governance in alignment with U.S. public company standards, with strategic oversight informed by regulatory requirements, reimbursement dynamics, and evolving patient care trends.